Atrium Therapeutics, Inc. (RNA) vs Sutro Biopharma, Inc. (STRO)
A side-by-side comparison of Atrium Therapeutics, Inc. and Sutro Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RNA
Atrium Therapeutics, Inc.
$8.03HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
STRO
Sutro Biopharma, Inc.
$14.66HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
Total return — RNA vs STRO
growth of $100 · dividends reinvested · last 1yRNA -46.0% (-46.0%/yr)STRO -26.1% (-26.1%/yr)STRO compounded faster over this window
RNA STRO
RNA vs STRO: by the numbers
- •STRO is the larger company ($142M vs $137M market cap).
- •Both run net losses; STRO's is the smaller (-395.25% vs -396.52% net margin).
Metrics side by side
Valuation
| Metric | RNA | STRO |
|---|---|---|
| P/S ratio | 5.85 | 3.10 |
| P/B ratio | 0.64 | N/A |
Profitability
| Metric | RNA | STRO |
|---|---|---|
| Gross margin | 97.90% | 97.20% |
| Operating margin | -410.23% | -102.41% |
| Net margin | -396.52% | -395.25% |
| ROE | -43.42% | N/A |
| ROIC | -38.45% | -100.04% |
Growth (annualized)
| Metric | RNA | STRO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 19.13% |
| Total return CAGR (5Y) | N/A | -39.51% |
Go deeper
Dig into the metrics
Atrium Therapeutics ROESutro Biopharma ROEAtrium Therapeutics operating marginSutro Biopharma operating marginAtrium Therapeutics revenue growthSutro Biopharma revenue growthAtrium Therapeutics free cash flowSutro Biopharma free cash flow
Atrium Therapeutics & Sutro Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.